



On track  Delay / risk of delay in non critical activities  Delay / risk of delay in critical activity or dependency  Completed		RRG Programmes & Projects Work the HRA is leading on (1/2)		Key Milestone  Dependency (colour indicates programme)			
	2023/24						
	Q1 (Apr-Jun)	Q2 (Jul-Sep)	Q3 (Oct-Dec)	Q4 (Jan-Mar)			
	STREAMLINED, EFFICIENT & INNOVATIVE CLINICAL RESEARCH						
UK Wide tools for		Model Agreements (P	ublished & Updated)				
study set up				WO ALCONOMICS OF THE PROPERTY			
ар							
Jeivice/		Ideal Path  Ideal	Case with				
	Combined review for	Ideal Path	acs Car				
	devices		IN CONTRACTOR OF THE PROPERTY				
Stream-		BUS					
lined		Sance B					
Research Support							
Services	<u>چ</u>	after the second					
	be an						
	70 6						





RRG Programmes & Projects On track Delay / risk of delay in non critical activities

Dependency

Work the HRA is leading on but is already reported in the main Portfolio Plan on slides 2 & 3 15/05/2023


2023/24


Q1 (Apr-Jun) Q2 (Jul-Sep) Q3 (Oct-Dec) Q4 (Jan-Mar)


IRAS website public Beta & IRAS Development (RSP)


Delay / risk of delay in critical activity or dependency


- To be updated once Business Case approved UK Clinical Trials Regulations Guidance & Implementation (UK Clinical Trials Legislation)
- **New approaches to Participant Information (Think Ethics)**











## **RAG Status Definitions**

	Green	Amber	Red
Cost	Within 10% +/-	Within 10% - 20% +/-	Over 20% +/- (unable to recover)
Time	On track	Delay in non critical activities	Delay in critical activity or dependency
Risks	<10	10-12	>15
Benefits	Benefits profiles and benefits realisation plan signed off, on benefits register	<ul> <li>Benefits in process of being defined</li> <li>Benefits defined but not signed off</li> <li>Benefits need reviewing</li> </ul>	<ul> <li>Benefits not defined / no benefits identified</li> <li>Benefits no longer valid</li> </ul>